Response Genetics' Q1 Revenues Fall 30 Percent | GenomeWeb

NEW YORK (GenomeWeb) – Response Genetics' first quarter revenues dropped 30 percent year over year despite an increase in its ResponseDX revenues, the company said today.

For the three months ended March 31, total revenues fell to $3.9 million from $5.6 million a year ago. ResponseDX revenues were up about 4 percent year over year to $3.3 million, but revenues from its pharmaceutical clients shrank by $1.9 million, Response said, due to the timing of services performed for the firm's largest pharma client.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.